MHC ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and MOG antibody disease
Recombinant polypeptides combining peptide antigens with HLA-G domains offer a novel approach to induce antigen-specific immunosuppression in multiple sclerosis and related autoimmune diseases, addressing the limitations of current treatments and potentially leading to improved clinical outcomes.
Patent Information
- Application Number
- PCT/EP2024/076383
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-09-22
- Filing Date
- 2024-09-20
- Publication Date
- 2025-03-27
AI Technical Summary
Current treatments for multiple sclerosis (MS), MOG antibody disease, and MOG antibody positive neuromyelitis optica are either insufficient in immunomodulation or come with severe side effects, and there is a need for improved therapeutic options that can effectively manage these autoimmune diseases.
The use of recombinant polypeptides comprising peptide antigens and domains of non-classical human major histocompatibility complex (MHC) class Ib molecules, such as HLA-G, to induce antigen-specific immunosuppression and tolerance, thereby modulating immune responses and reducing autoantibody formation.
The described approach effectively suppresses immune responses against myelin-specific antigens, potentially leading to improved clinical outcomes in patients with MS, MOG antibody disease, and MOG antibody positive neuromyelitis optica by reducing disease progression and minimizing severe side effects associated with conventional therapies.